ACHL
Price
$1.48
Change
+$0.01 (+0.68%)
Updated
Mar 20 closing price
Capitalization
63.22M
24 days until earnings call
AMGXF
Price
$0.36
Change
-$0.05 (-12.20%)
Updated
Dec 5 closing price
Capitalization
143.92M
Ad is loading...

ACHL vs AMGXF

Header iconACHL vs AMGXF Comparison
Open Charts ACHL vs AMGXFBanner chart's image
Achilles Therapeutics
Price$1.48
Change+$0.01 (+0.68%)
Volume$1.2M
Capitalization63.22M
AnGes MG
Price$0.36
Change-$0.05 (-12.20%)
Volume$2.05K
Capitalization143.92M
ACHL vs AMGXF Comparison Chart
Loading...
View a ticker or compare two or three
VS
ACHL vs. AMGXF commentary
Apr 19, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ACHL is a Hold and AMGXF is a Hold.

Ad is loading...
COMPARISON
Comparison
Apr 19, 2025
Stock price -- (ACHL: $1.48 vs. AMGXF: $0.36)
Brand notoriety: ACHL and AMGXF are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: ACHL: 76% vs. AMGXF: 100%
Market capitalization -- ACHL: $63.22M vs. AMGXF: $143.92M
ACHL [@Biotechnology] is valued at $63.22M. AMGXF’s [@Biotechnology] market capitalization is $143.92M. The market cap for tickers in the [@Biotechnology] industry ranges from $282.79B to $0. The average market capitalization across the [@Biotechnology] industry is $2.08B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

ACHL’s FA Score shows that 2 FA rating(s) are green whileAMGXF’s FA Score has 0 green FA rating(s).

  • ACHL’s FA Score: 2 green, 3 red.
  • AMGXF’s FA Score: 0 green, 5 red.
According to our system of comparison, ACHL is a better buy in the long-term than AMGXF.

Price Growth

ACHL (@Biotechnology) experienced а 0.00% price change this week, while AMGXF (@Biotechnology) price change was 0.00% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +7.03%. For the same industry, the average monthly price growth was -13.25%, and the average quarterly price growth was -24.49%.

Reported Earning Dates

ACHL is expected to report earnings on Aug 12, 2025.

Industries' Descriptions

@Biotechnology (+7.03% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

FUNDAMENTALS
Fundamentals
AMGXF($144M) has a higher market cap than ACHL($63.2M). ACHL YTD gains are higher at: 29.825 vs. AMGXF (0.000).
ACHLAMGXFACHL / AMGXF
Capitalization63.2M144M44%
EBITDA-67.33MN/A-
Gain YTD29.8250.000-
P/E RatioN/AN/A-
Revenue0N/A-
Total Cash86.1MN/A-
Total Debt3.62MN/A-
FUNDAMENTALS RATINGS
AMGXF: Fundamental Ratings
AMGXF
OUTLOOK RATING
1..100
50
VALUATION
overvalued / fair valued / undervalued
1..100
66
Overvalued
PROFIT vs RISK RATING
1..100
100
SMR RATING
1..100
96
PRICE GROWTH RATING
1..100
72
P/E GROWTH RATING
1..100
100
SEASONALITY SCORE
1..100
30

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

TECHNICAL ANALYSIS
Technical Analysis
ACHL
RSI
ODDS (%)
N/A
Stochastic
ODDS (%)
N/A
Momentum
ODDS (%)
N/A
MACD
ODDS (%)
N/A
TrendWeek
ODDS (%)
Bullish Trend about 1 month ago
76%
TrendMonth
ODDS (%)
Bullish Trend about 1 month ago
77%
Advances
ODDS (%)
N/A
Declines
ODDS (%)
N/A
BollingerBands
ODDS (%)
N/A
Aroon
ODDS (%)
N/A
View a ticker or compare two or three
Ad is loading...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
GME26.780.53
+2.02%
GameStop Corp
AAPL196.982.71
+1.39%
Apple
SPY526.410.75
+0.14%
SPDR® S&P 500® ETF
TSLA241.37-0.18
-0.07%
Tesla
BTC.X84450.805000-444.945300
-0.52%
Bitcoin cryptocurrency

ACHL and

Correlation & Price change

A.I.dvisor indicates that over the last year, ACHL has been loosely correlated with EWTX. These tickers have moved in lockstep 37% of the time. This A.I.-generated data suggests there is some statistical probability that if ACHL jumps, then EWTX could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ACHL
1D Price
Change %
ACHL100%
N/A
EWTX - ACHL
37%
Loosely correlated
+3.22%
KANT - ACHL
29%
Poorly correlated
N/A
RNTX - ACHL
27%
Poorly correlated
+3.03%
VKTX - ACHL
26%
Poorly correlated
+1.44%
ANEB - ACHL
25%
Poorly correlated
-2.88%
More

AMGXF and

Correlation & Price change

A.I.dvisor indicates that over the last year, AMGXF has been loosely correlated with EWTX. These tickers have moved in lockstep 35% of the time. This A.I.-generated data suggests there is some statistical probability that if AMGXF jumps, then EWTX could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To AMGXF
1D Price
Change %
AMGXF100%
N/A
EWTX - AMGXF
35%
Loosely correlated
+3.22%
APLT - AMGXF
32%
Poorly correlated
+9.61%
PRTG - AMGXF
28%
Poorly correlated
+16.15%
XCUR - AMGXF
27%
Poorly correlated
-26.93%
ACHL - AMGXF
23%
Poorly correlated
N/A
More